Small-molecule drugs development for Alzheimer's disease
Weiwei Yao1, Huihui Yang1, Jinfei Yang1
1School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China.
Frontiers in Aging Neuroscience
|November 17, 2022
Summary
This review explores small-molecule drugs targeting Alzheimer's disease (AD) pathogenesis, including beta-amyloid and tau proteins. It aims to advance understanding and treatment development for this neurodegenerative disorder.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no effective cures.
- Key pathological hallmarks include beta-amyloid (Aβ) cascade and hyperphosphorylated tau protein.
- Other contributing factors investigated include oxidative stress, neurotransmitter deficiency, mitochondrial dysfunction, and inflammation.
Purpose of the Study:
- To review small-molecule drugs developed based on AD pathogenesis.
- To deepen the understanding of Alzheimer's disease mechanisms.
- To aid researchers in developing novel and improved therapeutic strategies.
Main Methods:
- Literature review of scientific publications.
- Analysis of small-molecule drug development pathways.
- Synthesis of current knowledge on AD pathophysiology and drug targets.
Main Results:
- Identified various small-molecule drug candidates targeting different AD pathways.
- Highlighted the complexity of AD pathophysiology and the need for multi-targeted approaches.
- Summarized the current status and challenges in AD drug development.
Conclusions:
- Small-molecule drugs targeting specific AD pathologies show therapeutic potential.
- A comprehensive understanding of AD mechanisms is crucial for effective treatment development.
- Continued research is essential to discover and refine treatments for Alzheimer's disease.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
242
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
242
01:26Alzheimer's Disease: Overview
621
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
621
02:30siRNA - Small Interfering RNAs
16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
01:26Drug Discovery: Overview
8.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.3K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
183
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
183